Patient
SITE011-0107
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE011 (ITA) (Dr. Jansen)
consented 2026-01-08
Adverse events
8
Serious AEs
3
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-10-04 (study day 79); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-10-04 (study day 79); relationship: NOT RELATED
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-14 (study day 59); relationship: RELATED; serious criteria: life-threatening
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-05 (study day 50); relationship: NOT RELATED
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-08-22 (study day 36); relationship: not assessed
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-08-20 (study day 34); relationship: NOT RELATED; serious criteria: life-threatening
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-29 (study day 12); relationship: not assessed; serious criteria: hospitalization
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-07-28 (study day 11); relationship: RELATED
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.